Robert E. Burrier

Dr. Burrier is a career technology executive in pharmaceutical research, biosupplier product development, and biotech services. He participated in over 150 drug discovery programs at Schering-Plough, Eli Lilly, GelTex, and Genzyme. In fact, Dr. Burrier participated in and led programs for drugs on the market, including Zetia and Vytorin.

Dr. Burrier’s work in biosupplier product development includes leading teams at Invitrogen and EMD Millipore (Merck) to innovate in cell biology, cell media development, assay development, and workflow improvements. The markets for these programs included academic and industrial cell biology research, stem cells, regenerative medicine, and biotherapeutic protein production.

At Stemina, Dr. Burrier has grown and integrated the company’s cell-based, analytical, and informatics capabilities to ensure its platform can tackle complex metabolic problems. Stemina developed stem cell-based assays for developmental toxicity and cardiotoxicity. He also leads the metabolomics efforts in NeuroPointDX, Stemina’s neurological disorders diagnostic division. Its first program uncovered biomarkers that identify metabolic subtypes of autism.